Diamond Hill Capital Management Inc. Has $750.54 Million Holdings in Abbott Laboratories $ABT

Diamond Hill Capital Management Inc. lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,603,583 shares of the healthcare product maker’s stock after selling 309,225 shares during the quarter. Abbott Laboratories makes up approximately 3.6% of Diamond Hill Capital Management Inc.’s portfolio, making the stock its 3rd largest holding. Diamond Hill Capital Management Inc.’s holdings in Abbott Laboratories were worth $750,544,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Charles Schwab Trust Co lifted its position in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after buying an additional 15,394 shares during the last quarter. Asset Management One Co. Ltd. increased its holdings in shares of Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after acquiring an additional 19,966 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of Abbott Laboratories by 6.1% in the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after acquiring an additional 18,974 shares in the last quarter. AE Wealth Management LLC lifted its holdings in Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after purchasing an additional 11,264 shares during the last quarter. Finally, iA Global Asset Management Inc. boosted its position in Abbott Laboratories by 94.0% during the third quarter. iA Global Asset Management Inc. now owns 144,062 shares of the healthcare product maker’s stock worth $19,296,000 after purchasing an additional 69,803 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Up 1.6%

Shares of NYSE ABT opened at $110.86 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $192.77 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 1.76 and a beta of 0.75. The firm’s 50-day moving average is $120.86 and its 200-day moving average is $126.90. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Insider Activity at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The shares were acquired at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. The trade was a 0.15% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ABT. Oppenheimer reduced their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Argus reduced their price objective on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Evercore lowered their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Leerink Partners reduced their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Finally, Citigroup lowered their price target on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.